JP2005528337A5 - - Google Patents

Download PDF

Info

Publication number
JP2005528337A5
JP2005528337A5 JP2003558463A JP2003558463A JP2005528337A5 JP 2005528337 A5 JP2005528337 A5 JP 2005528337A5 JP 2003558463 A JP2003558463 A JP 2003558463A JP 2003558463 A JP2003558463 A JP 2003558463A JP 2005528337 A5 JP2005528337 A5 JP 2005528337A5
Authority
JP
Japan
Prior art keywords
xaa
gly
ser
glp
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003558463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005528337A (ja
JP4282485B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/000001 external-priority patent/WO2003058203A2/en
Publication of JP2005528337A publication Critical patent/JP2005528337A/ja
Publication of JP2005528337A5 publication Critical patent/JP2005528337A5/ja
Application granted granted Critical
Publication of JP4282485B2 publication Critical patent/JP4282485B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003558463A 2002-01-08 2003-01-03 伸長グルカゴン様ペプチド−1アナログ Expired - Fee Related JP4282485B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34647402P 2002-01-08 2002-01-08
US40509702P 2002-08-21 2002-08-21
PCT/US2003/000001 WO2003058203A2 (en) 2002-01-08 2003-01-03 Extended glucagon-like peptide-1 analogs

Publications (3)

Publication Number Publication Date
JP2005528337A JP2005528337A (ja) 2005-09-22
JP2005528337A5 true JP2005528337A5 (cg-RX-API-DMAC7.html) 2006-02-02
JP4282485B2 JP4282485B2 (ja) 2009-06-24

Family

ID=26994870

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003558463A Expired - Fee Related JP4282485B2 (ja) 2002-01-08 2003-01-03 伸長グルカゴン様ペプチド−1アナログ

Country Status (11)

Country Link
US (1) US7482321B2 (cg-RX-API-DMAC7.html)
EP (1) EP1585959A4 (cg-RX-API-DMAC7.html)
JP (1) JP4282485B2 (cg-RX-API-DMAC7.html)
AR (1) AR038102A1 (cg-RX-API-DMAC7.html)
AU (1) AU2003200839B2 (cg-RX-API-DMAC7.html)
BR (1) BR0306706A (cg-RX-API-DMAC7.html)
CA (1) CA2468700A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA04006679A (cg-RX-API-DMAC7.html)
PE (1) PE20030820A1 (cg-RX-API-DMAC7.html)
TW (1) TW200306202A (cg-RX-API-DMAC7.html)
WO (1) WO2003058203A2 (cg-RX-API-DMAC7.html)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7557183B2 (en) 2003-03-19 2009-07-07 Eli Lilly And Company Polyethylene glycol linked GLP-1 compounds
EP2298337B1 (en) 2003-12-09 2017-02-22 Novo Nordisk A/S Regulation of food preference using GLP-1 agonists
EP1709071A4 (en) * 2004-01-08 2007-05-30 Theratechnologies Inc GLUCAGON LIKE PEPTIDE-1 ANALOGS WITH LONG PERFORMANCE
EP1758575A1 (en) 2004-06-11 2007-03-07 Novo Nordisk A/S Counteracting drug-induced obesity using glp-1 agonists
WO2006023358A1 (en) * 2004-08-18 2006-03-02 Eli Lilly And Company Selective vpac2 receptor peptide agonists
EP1845105A4 (en) 2005-01-14 2009-02-18 Wuxi Grandchamp Pharmaceutical MODIFIED EXENDINES AND CORRESPONDING USES
KR20070120112A (ko) 2005-03-18 2007-12-21 노보 노르디스크 에이/에스 연장형 glp-1 화합물
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
CA2606894A1 (en) * 2005-05-05 2007-02-15 Cadila Healthcare Limited Novel compounds as glp-i agonists
CN101166545B (zh) * 2005-05-13 2011-06-15 伊莱利利公司 Glp-1聚乙二醇化的化合物
WO2007021498A1 (en) * 2005-08-11 2007-02-22 Eli Lilly And Company Selective vpac2 receptor peptide agonists
ES2336575T3 (es) 2005-09-22 2010-04-14 Biocompatibles Uk Limited Polipeptidos de fusion glp-1 (peptido-1 similar al glucagon) con resistencia aumentada a la peptidasa.
AU2006306236B2 (en) 2005-10-26 2011-12-01 Eli Lilly And Company Selective VPAC2 receptor peptide agonists
HUE029798T2 (en) * 2005-11-04 2017-03-28 Glaxosmithkline Llc Methods of administering hypoglycemic agents
US8338368B2 (en) 2005-11-07 2012-12-25 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
JP5096363B2 (ja) 2005-12-16 2012-12-12 ネクター セラピューティックス Glp−1のポリマ複合体
US20100048460A1 (en) * 2006-02-28 2010-02-25 Lianshan Zhang Selective vpac2 receptor peptide agonists
WO2007113205A1 (en) * 2006-04-03 2007-10-11 Novo Nordisk A/S Glp-1 peptide agonists
CA2648936C (en) 2006-04-20 2013-07-09 Amgen Inc. Glp-1 compounds
DE602006009631D1 (de) 2006-05-10 2009-11-19 Biocompatibles Uk Ltd GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
PE20121528A1 (es) * 2006-09-13 2012-12-12 Smithkline Beecham Corp Metodos para administrar agentes hipoglucemiantes de larga duracion
US8454971B2 (en) 2007-02-15 2013-06-04 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
EP1972349A1 (en) * 2007-03-21 2008-09-24 Biocompatibles UK Limited GLP-1 fusion peptides conjugated to polymer(s), their production and use
EP1975176A1 (en) * 2007-03-27 2008-10-01 Biocompatibles UK Limited Novel glp-1 fusion peptides, their production and use
CA2693504A1 (en) 2007-08-03 2009-02-12 Eli Lilly And Company Treatment for obesity
ES2558155T3 (es) 2007-10-30 2016-02-02 Indiana University Research And Technology Corporation Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1
TWI474835B (zh) 2008-06-17 2015-03-01 Univ Indiana Res & Tech Corp 用於治療代謝病症及肥胖症之基於gip之混合激動劑
KR20110039230A (ko) * 2008-06-17 2011-04-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 생리학적 pH 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체
US8889618B2 (en) 2008-11-07 2014-11-18 The General Hospital Corporation C-terminal fragments of glucagon-like peptide-1 (GLP-1)
ES2620610T3 (es) 2008-12-10 2017-06-29 Glaxosmithkline Llc Composiciones farmacéuticas de albiglutide
RU2550696C2 (ru) 2008-12-19 2015-05-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Основанные на амидах пролекарства пептидов глюкагонового надсемейства
EP2443146B1 (en) 2009-06-16 2016-10-05 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
IN2012DN06437A (cg-RX-API-DMAC7.html) 2010-01-27 2015-10-09 Univ Indiana Res & Tech Corp
US8691763B2 (en) 2010-05-04 2014-04-08 Glaxosmithkline Llc Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
CN103079587B (zh) 2010-05-13 2016-05-11 印第安纳大学研究及科技有限公司 呈现核激素受体活性的胰高血糖素超家族肽
KR20130111923A (ko) 2010-05-13 2013-10-11 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 G-단백결합 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
RU2580317C2 (ru) 2010-06-24 2016-04-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов
WO2012054861A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Glp-1 polymer conjugates having a releasable linkage
WO2012054822A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Pharmacologically active polymer-glp-1 conjugates
US9040481B2 (en) 2010-11-02 2015-05-26 The General Hospital Corporation Methods for treating steatotic disease
TWI538687B (zh) 2010-11-24 2016-06-21 杜瑞克公司 生物可降解之藥物遞送組成物
EA201390941A1 (ru) 2010-12-22 2013-12-30 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, проявляющие активность на рецепторе gip
BR112013032717A2 (pt) 2011-06-22 2017-01-24 Univ Indiana Res & Tech Corp coagonistas do receptor de glucagon/glp-1
EA031230B1 (ru) 2011-06-22 2018-12-28 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Агонисты глюкагонового рецептора/glp-1-рецептора
EP2729157B1 (en) * 2011-07-06 2019-01-16 The General Hospital Corporation A pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) for use in treatment
CN102363633B (zh) * 2011-11-16 2013-11-20 天津拓飞生物科技有限公司 胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
CN103957927B (zh) 2011-11-17 2016-11-09 印第安纳大学研究及科技有限公司 呈现糖皮质激素受体活性的胰高血糖素超家族肽
WO2013078396A2 (en) 2011-11-23 2013-05-30 Durect Corporation Radiation-sterilized biodegradable drug delivery compositions
EP2864351B1 (en) 2012-06-21 2016-08-10 Indiana University Research and Technology Corporation Glucagon analogs exhibiting gip receptor activity
ES2646538T3 (es) * 2013-06-20 2017-12-14 Novo Nordisk A/S Derivados de GLP-1 y sus usos
CA2932477C (en) 2013-12-06 2023-10-10 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
US20160303242A1 (en) 2013-12-09 2016-10-20 Durect Corporation Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
ES2739289T3 (es) 2014-11-27 2020-01-30 Novo Nordisk As Derivados de GLP-1 y sus usos
CN107108714B (zh) 2014-12-17 2022-02-08 诺和诺德股份有限公司 Glp-1衍生物及其用途
HUE067499T2 (hu) 2018-04-05 2024-10-28 Sun Pharmaceutical Ind Ltd Új GLP-1 analógok

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69737479T4 (de) * 1996-08-30 2010-05-06 Novo Nordisk A/S Glp-1 derivate
ATE466027T1 (de) * 1998-02-27 2010-05-15 Novo Nordisk As Abkömmlinge von glp-1 analogen
WO1999043707A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally modified glp-1 derivatives
EP1306091A3 (en) 1998-07-31 2003-05-21 Novo Nordisk A/S Stimulation of beta cell proliferation
DK1355942T3 (da) * 2000-12-07 2008-11-17 Lilly Co Eli GLP-1-fusionsproteiner
EP2022505B1 (en) * 2001-07-31 2011-12-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services GLP-1, exendin-4, peptide analogs and uses thereof
US7238663B2 (en) * 2001-08-28 2007-07-03 Eli Lilly And Company Pre-mixes of GLP-1 and basal insulin
EP1448222A4 (en) * 2001-10-19 2006-05-17 Lilly Co Eli BIPHASIC MIXTURES OF GLP-1 AND INSULIN

Similar Documents

Publication Publication Date Title
JP2005528337A5 (cg-RX-API-DMAC7.html)
JP2010538049A5 (cg-RX-API-DMAC7.html)
JP2008533105A5 (cg-RX-API-DMAC7.html)
EP3398961B1 (en) Triple activator activating glucagon, glp-1 and gip receptor
CN101993485B (zh) 促胰岛素分泌肽类似物同源二聚体及其用途
JP2014529629A5 (cg-RX-API-DMAC7.html)
JP2003505347A5 (cg-RX-API-DMAC7.html)
JP2001011095A5 (cg-RX-API-DMAC7.html)
CN102348715B (zh) 延伸重组多肽和包含该延伸重组多肽的组合物
JP4282485B2 (ja) 伸長グルカゴン様ペプチド−1アナログ
CN101108878B (zh) 胰高血糖素样肽-1的类似物
JP2013517307A5 (cg-RX-API-DMAC7.html)
RU2007134156A (ru) Ацилированные glp-1 соединения
JP2013543853A5 (cg-RX-API-DMAC7.html)
EP2844269A1 (en) Transmucosal delivery of engineered polypeptides
JP2004509079A5 (cg-RX-API-DMAC7.html)
TW201010729A (en) GIP-based mixed agonists for treatment of metabolic disorders and obesity
CN104271588A (zh) 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
JP2005514060A5 (cg-RX-API-DMAC7.html)
JP2014501712A5 (cg-RX-API-DMAC7.html)
AU2003200839A2 (en) Extended glucagon-like peptide-1 analogs
JP2023510218A (ja) 長時間作用型glp-1化合物
JP2012529297A5 (cg-RX-API-DMAC7.html)
JP2005519059A5 (cg-RX-API-DMAC7.html)
RU2005115477A (ru) Нейтрализующие антитела против gdf-8 и их применение